TGF-β is upregulated in liver cancer tissue and elevated in the plasma of liver cancer patients [7,8], and is reported to activate multiple signaling pathways, including Smad-dependent and Smad-independent pathways involving liver cancer progression. Here, TGFB1 is linked to liver cancer.